Longitudinal Cognitive Screening Findings in Pediatric MS vs. Pediatric Controls and Adult MS in a Multi-center Cohort (S31.008)

Abstract

<h3>Objective:</h3> To compare longitudinal cognitive performance between pediatric patients with relapsing remitting multiple sclerosis (RRMS), pediatric healthy controls (HC), and adult patients with RRMS. <h3>Background:</h3> Pediatric MS affects the brain at an important time of development in children and teenagers. Studies of cognition in these patients have provided mixed results. <h3>Design/Methods:</h3> Consecutively eligible pediatric MS patients (n=71), pediatric healthy peers (n=99), and adult MS patients (n=66) enrolled across seven centers from the US Network of Pediatric MS Centers underwent a cognitive screening battery at baseline and 1.5–3.5 years later. Baseline cognitive test results were previously reported. Longitudinal findings on the individual measures of the BICAMS (Brief International Cognitive Assessment for MS) and Cogstate Brief Battery (CBB) were analyzed using z-scores based on available normative data. <h3>Results:</h3> 87% of pediatric MS patients, 82% of pediatric controls, and 73% of adult MS patients returned for follow-up after a mean of 2.15 years. Those who returned had baseline demographic characteristics similar to those who did not return. The mean change in z-scores at the end of the study for the pediatric MS patients did not differ from pediatric controls on the BICAMS or Cogstate batteries: Symbol Digit Modalities Test (SDMT) (−0.4 vs. 0.1, p=0.20); Rey Auditory Verbal Learning Test (RAVLT) (−0.6 vs. −0.6, p=0.90); and the Brief Visuospatial Memory Test-Revised (BVMT-R) (−0.0 vs. 0.1, p=0.52). Pediatric vs. adult cases showed no differences in mean change in z-scores, except on the RAVLT, where both pediatric MS and pediatric controls declined to a greater degree than adults with MS (p=0.007). <h3>Conclusions:</h3> This study showed relative stability in cognitive performance among pediatric and adult cases of RRMS and pediatric controls. It is reassuring that many with pediatric MS show preserved cognitive function relative to healthy peers early in their short-term disease course. <b>Disclosure:</b> Dr. O’Neill has nothing to disclose. Dr. Charvet has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Johnson &amp; Johnson. Dr. Charvet has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Springer Healthcare. Dr. Charvet has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for YBrain. Dr. Charvet has stock in Johnson&amp;Johnson. Michael Waltz has nothing to disclose. Dr. Casper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aperta Biosciences. Dr. Casper has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for After Hours Medical. The institution of Dr. Casper has received research support from NIH. The institution of Dr. Casper has received research support from The National Multiple Sclerosis Society. The institution of Dr. Casper has received research support from Roche. Allan George has nothing to disclose. The institution of Dr. Benson has received research support from ROHHAD Fight, Inc. The institution of Dr. Benson has received research support from Shore Foundation. The institution of Dr. Benson has received research support from Alexion Pharmacuticals. The institution of Dr. Benson has received research support from Biogen, Inc. The institution of Dr. Benson has received research support from NIH. Dr. Benson has received personal compensation in the range of $0-$499 for serving as a consultant with MA Department of public health. Dr. Benson has received personal compensation in the range of $5,000-$9,999 for serving as a consultant with National vaccine injury compensation program. The institution of Dr. Gorman has received research support from Pfizer. The institution of Dr. Gorman has received research support from Roche / Genetech . Dr. Goyal has received stock or an ownership interest from IBM. The institution of Dr. Goyal has received research support from NIH. Dr. Goyal has received personal compensation in the range of $0-$499 for serving as a Conference attendee with Capital Medical University, Shandong Madic Technology Co Ltd, Tancheng Talent Office. The institution of Dr. Mar has received research support from NIH. An immediate family member of Dr. Ness has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jan One. The institution of Dr. Ness has received research support from Chugai/Roche. The institution of Dr. Ness has received research support from National Multiple Sclerosis Society. The institution of an immediate family member of Dr. Ness has received research support from NIH. An immediate family member of Dr. Ness has received publishing royalties from a publication relating to health care. The institution of Dr. Schreiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CDC. Dr. Schreiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Schreiner has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Mary C Bush, LLC. The institution of Dr. Schreiner has received research support from Roche Genentech. Dr. Waubant has received personal compensation in the range of $500-$4,999 for serving as a Consultant for emerald pharmaceuticals. Dr. Waubant has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for elsevier. The institution of Dr. Waubant has received research support from NIH. The institution of Dr. Waubant has received research support from NMSS. The institution of Dr. Waubant has received research support from PCORI. The institution of Dr. Waubant has received research support from Race to Erase MS. The institution of Dr. Waubant has received research support from Roche. The institution of Dr. Waubant has received research support from Biogen. The institution of Dr. Waubant has received research support from Department of Defense. Dr. Waubant has received publishing royalties from a publication relating to health care. Dr. Weinstock-Guttman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme &amp;Sanofi. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving as a Reviewer with NIH. Yolanda Wheeler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene Corporation. Yolanda Wheeler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Banner Life Sciences. Yolanda Wheeler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mutliple Sclerosis Association of America. Yolanda Wheeler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Multiple Sclerosis Association of America. The institution of Yolanda Wheeler has received research support from National MS Society. The institution of Yolanda Wheeler has received research support from National MS Society. Dr. Aaen has nothing to disclose. Dr. Abrams has nothing to disclose. Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Chitnis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche-Genentech. Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Academic CME. The institution of Dr. Chitnis has received research support from Novartis. The institution of Dr. Chitnis has received research support from Sanofi. The institution of Dr. Chitnis has received research support from Octave. Dr. Lotze has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Department of Justice VICP. The institution of Dr. Lotze has received research support from NIH. The institution of Dr. Lotze has received research support from National MS Society. The institution of Dr. Lotze has received research support from Sarepta Therapeutics. The institution of Dr. Lotze has received research support from PTC THERAPEUTICS. The institution of Dr. Lotze has received research support from Avexis. Dr. Lotze has received publishing royalties from a publication relating to health care. Dr. Rensel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Rensel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cycle Pharma. Dr. Rensel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biogen. Dr. Rensel has stock in Brain Ops Group LLC. Dr. Rensel has stock in Brain Fresh LLC . The institution of Dr. Rensel has received research support from NMSS. The institution of Dr. Rensel has received research support from Biogen. The institution of Dr. Rensel has received research support from genentech. Dr. Rodriguez has received intellectual property interests from a discovery or technology relating to health care. The institution of Dr. Rose has received research support from National Multiple Sclerosis Society. The institution of Dr. Rose has received research support from Guthy Jackson Charitable Foundation. The institution of Dr. Rose has received research support from NIH . The institution of Dr. Rose has received research support from VA. The institution of Dr. Rose has received research support from Biogen. The institution of Dr. Rose has received research support from Friends of MS. Dr. Rose has received intellectual property interests from a discovery or technology relating to health care. Dr. Shukla has nothing to disclose. Dr. Tillema has nothing to disclose. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lerhman. Dr. Krupp has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for medscape. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NeuroLive. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Krupp has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Cleveland Clinic. Dr. Krupp has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for MCIC. The institution of Dr. Krupp has received research support from Biogen. The institution of Dr. Krupp has received research support from National Multiple Sclerosis Society. Dr. Krupp has received intellectual property interests from a discovery or technology relating to health care.